OSLO, Norway, Sept. 12, 2018 /PRNewswire/ -- Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard to treat solid tumors, is pleased to note that pre-clinical data from its ONCOS oncolytic virus program has been published in two...
For more information, please visit
https://www.prnewswire.com:443/news-rele[...]er-gene-therapy-300710957.html